Protein tyrosine phosphatase 1B (PTP-1B) has attracted interest as a novel target for the treatment of type 2 diabetes, this because its role in the insulin-signaling pathway as a negative regulator. Thus, the aim of current work was to obtain seven ursolic acid derivatives as potential antidiabetic agents with PTP-1B inhibition as main mechanism of action. Furthermore, derivatives 1-7 were submitted in vitro to enzymatic PTP-1B inhibition being 3, 5, and 7 the most active compounds (IC 50 5 5.6, 4.7, and 4.6 lM, respectively). In addition, results were corroborated with in silico docking studies with PTP-1B orthosteric site A and extended binding site B, showed that 3 had polar and Van der Waals interactions in both sites with Lys120, Tyr46, Ser216, Ala217, Ile219, Asp181, Phe182, Gln262, Val49, Met258, and Gly259, showing a docking score value of 27.48 Kcal/mol, being more specific for site A. Moreover, compound 7 showed polar interaction with Gln262 and Van der Waals interactions with Ala217, Phe182, Ile219, Arg45, Tyr46, Arg47, Asp48, and Val49 with a predictive docking score of 26.43 kcal/mol, suggesting that the potential binding site could be localized in the site B adjacent to the catalytic site A. Finally, derivatives 2 and 7 (50 mg/kg) were selected to establish their in vivo antidiabetic effect using a noninsulin-dependent diabetes mice model, showing significant blood glucose lowering compared with control group (p < .05). K E Y W O R D S antidiabetic agents, docking, pentacyclic acid triterpenes, PTP-1B inhibition, ursolic acid derivatives *The same level of participation as the principal and correspondence author is considered. Drug Dev. Res.. 2018;1-11. wileyonlinelibrary.com/journal/ddr Chemical shifts are given in values of part per million, referenced to tetramethylsilane (TMS) as an internal standard. 2.2 | Synthesis of ursolic acid derivatives 2.2.1 | Starting material Ursolic acid was purchased from Sigma-Aldrich (St. Louis, MO). Chemical reagents were purchased analytical grade from Sigma-Aldrich, Mexico. Commercially available solvents (n-hexane, ethyl acetate, and acetone) were used after purification and dried according to standard procedures.
| I NTR OD U CTI ON
According to the World Health Organization, the chronic degenerative diseases represent the main causes of death in the world. Diabetes is a metabolic disease, which is characterized by an impaired regulation of glucose, and additionally, lipids and proteins (Mahapatra, Asati, & Bharti, 2015) . This because insulin is not able to perform its function as main metabolic regulator in peripheral tissues, because of lack of insulin (type 1 diabetes) or because of resistance to insulin action and/or impaired insulin secretion (type 2 diabetes). Diabetes increases the risk to develop micro and macrovascular complications such as neuropathy, nephropathy and retinopathy, triggering consequences like cardiovascular diseases (myocardial infarction, stroke, among others), blindness, limb amputation, and end-stage renal disease (Brownlee, 2001) . Moreover, diabetes has been linked to central nervous system diseases like depression and cognition disturbances (Li, Zhang, & Sima, 2007) .
Despite the availability of drugs for the treatment of diabetes, many of them fail because two frequent reasons (Tahrani, Bailey, Del Prato, & Barnett, 2011) : (a) many drugs cause diverse side-effects, that is, hypoglycemia, edema, weight gain, increasing cardiovascular risk, which can limit its use for the patient; (b) the improvement in the control of glycaemia is not continuous, due to the degenerative features related with the disease, thus, eventually it is necessary to increase the dose of the drug used or combinatorial therapy is needed to increase control. Thus, currently it is necessary to develop new drugs that counteract these points, and/or to obtain novel drugs which act at new targets. In this context, protein tyrosine phosphatase 1B (PTP-1B) has recently shown an important influence over insulin sensitivity, since it is implicated in modulating insulin signal transduction becoming a key regulator of insulin-receptor activity, and downstream signaling pathways (Johnson, Ermolieff, & Jirousek, 2002) . This is related with a dephosphorylation of active insulin receptor (IR) (Romsicki, Reece, Gauthier, Asante-Appiah, & Kennedy, 2004) . Also, PTP-1B is implicated in the regulation of the leptin receptor, which is involved in food intake regulation by CNS (Klok, Jakobsdottir, & Drent, 2007) . PTP-1B is an enzyme formed by 435 amino acids residues, which is anchored into cytoplasmic face of endoplasmic reticulum (Johnson et al., 2002) and presents two important regions, sites A (catalytic) and B (extended binding pocket). The A site is formed by 214-221 residues and catalyzes the dephosphorilation of tyrosine arylphosphate residues (Tonks, 2003) . The second region (B site), is an extended binding site but inactive region next to A site, which only binds to arylphosphate groups (Puius et al., 1997) . Then, inhibition of PTP-1B could be a very important target to develop new antidiabetic drugs. There are several synthetic and natural derived compounds which are described as PTP-1B inhibitors (Verma, Gupta, Chaudhary, & Garg, 2017) .
Natural products represent a great source for to study and develop new drugs candidates for the treatment of diabetes (Liu, Chen, Hu, Guo, & Shen, 2010) . Ursolic acid (UA) is a triterpene that has shown metabolic (Sheng & Sun, 2011 ), cardiovascular (Aguirre-Crespo et al., 2006 Rios et al., 2012; Somova, Nadar, Rammanan, and Shode, 2003a; Somova, Shode, Ramnanan, & Nadar, 2003b) , antibacterial (Nascimento et al., 2014) , antifungal (Innocente et al., 2014) , cytotoxic (Li et al., 2014) , antidepressant (Colla et al., 2014; Machado et al., 2012) , antioxidant and antiatherogenic effects (Allouche, Beltr an, Gaforio, Uceda, & Mesa, 2010) , among others, which makes it an important scaffold in medicinal chemistry. Currently, is known that the ursolic acid antidiabetic effect is mediated by its interaction with different targets: UA acts as insulinomimetic (Jung et al., 2007) , increasing the autophosphorylation and activation of insulin receptor, and also proceeds as insulin sensitizer since it is able to inhibit the PTP-1B enzyme (Ramírez-Espinosa et al., 2011; Zhang et al., 2006) . A recent report showed that UA augments GLUT4 as a result of increasing intracellular Ca 21 concentration, which augments movement and translocation of GLUT4 transporter unto membrane (Castro et al., 2015) . Other UA direct and indirect antidiabetic mechanisms are enzymatic inhibition of: 11b-HSD1 (Rollinger et al., 2010) , glycogen phosphorylase (Jang, Kim, Choi, Kwon, & Lee, 2010) , a-glucosidase (Wu, Zhang, Lu, He, & Zhao, 2014) , and aldose reductase (Lee et al., 2014) . Thus, the aim of current work was to synthesize new UA derivatives based on this scaffold in order to discover more potent, specific and effective antidiabetic bioactive compounds.
| M E TH ODS A N D M AT ER I AL S

| General
The preparation of 1-6 UA derivatives was carried out in a CEM Dis- over period of 5 min, then the reaction mixture was placed under microwave radiation in CEM equipment at 608C. Solvent was eliminated under vacuum and the reaction crude was purified by FCC.
(3b)-3-methoxyursen-12-en-28-oic acid (1)
UA 120 mg (0.263 mmol), THF (2 mL), Na 15.1 mg (0.657 mmol), methyl iodide 35 lL (0.552 mmol), 2 h reaction. FCC (n-hexane/acetone 90:10 v/v) affording 80.4 mg product, 65% yield, TLC: (C-10), 36.8 (C-22), 33.2 (C-7), 30.9 (C-21), 28.3 (C-23), 28.2 (C-15), 27.4 (C-2), 24.4 (C-16), 23.8 (C-27), 23.5 (C-11), 21.4 (C-30), 18.5 (C-6), 17.2 (C-26), 17.1 (C-29), 15.8 (C-25), 15.6 (C-24).
| Synthesis procedure for compound 3, 4, and 5
In a well-stirred and cooled solution of UA (1.0 equiv.) in dry CH 2 Cl 2 and DMF was added 2.1 equiv. of the corresponding base. Mixture reaction was stirred at 08C for 30 min. Acyl halide (2.1 equiv.) was added dropwise over a 5 min period, then, the reaction mixture was placed under microwave radiation in CEM equipment at 608C. Solvent was eliminated under vacuum and the reaction crude was purified by FCC. (3b)-ursen-12-en-3,28-diol (7) A cooled solution of LiAlH 4 (180 mg, 4.743 mmol) in dry THF (10 mL) was added dropwise to a mixture of UA (500 mg, 1.085 mmol) and dry THF (5 mL 
| PTP-1B inhibition assay
The assays were carried out at 378C. The substrate ( 
| Animals
Male CD1 mice weighing 30-40 g body weight were housed at standard laboratory conditions and fed with a rodent pellet diet and water ad libitum. They were maintained at room temperature and a photoper- 
| In vivo antidiabetic assay
A described protocol was used (Ch avez- Silva et al., 2018) . In brief, fasted diabetic mice were divided into groups of six animals each. The groups were orally administered with a suspension of compounds 2 and 7 prepared in 10% Tween 80 (50 mg/kg). Glibenclamide was used as hypoglycemic reference drug (3 mg/kg). Control group was treated with 10% Tween 80. Glucose concentration was determined from mice tail at 0, 1, 3, 5, and 7 h after administration with a glucometer (Roche The number of docking runs was 100, all solutions were clustered into groups with RMS lower than 1 after docking and the clusters were ranked by the lowest energy representative of each cluster. In order to describe the ligand-binding pocket interactions, the top ranked binding mode found by AutoDock in complex with the selected binding region of PTP-1B was subject to full energy minimization using MMFF94 force field. PyMOL 1.0 was used to generate the molecular surface of docking models.
| Docking
| R ESUL TS A N D DI SCUSSION
| Chemistry
In our research, seven semisynthetic UA derivatives were prepared (Schemes 1 and 2), consisting in two ethers and three esters on C-3 hydroxyl group, the methyl ester and the corresponding alcohol from the reduction of C-28 carboxylic acid group. From them, ester and ether derivatives (compounds 1-6) were prepared using microwave (MW) assisted synthesis procedure according to reports for some oleanolic and moronic acids derivatives (Cer on-Romero et al., 2016; -Espinosa et al., 2014) , and a conventional synthesis for compound 7. The 3-acyloxy derivatives 3 and 5 were prepared through the reaction of UA with the respective acyl chlorides, meanwhile the ethers derivatives (1 and 2) and the ursolic acid methyl ester (6) were obtained by reaction with alkyl halide, in the presence of the corresponding base. Compound 4 was prepared by reaction between DMF in presence of benzoyl chloride as catalyst through Vilsmeier reaction. These reactions were subjected to microwave irradiation at 608C. This methodology allowed an improved performance in the reaction times, that is, less than 3 h, although the yields were variable ( 
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| In vitro PTP-1B inhibition assay
The inhibitory properties of these compounds against PTP-1B was screened. The initial enzymatic assays were carried out at fixed concentration of p-nitrophenylphosphate (2.5 mM) in the presence of 25 lM of each UA derivative. As can be seen in Figure 1 , compounds 3, 5, and 7 were the most active; in fact, they strongly inhibit 95-99% of the enzyme activity respect to the control test DMSO; meanwhile, compound 2 was a medium inhibitor (<60%). On the other hand, compounds 1, 4, and 6 were weaker inhibitors with enzyme inhibition values minor than 30%.
In order to obtain the IC 50 value for each UA derivative, the enzymatic activity of PTP-1B in the presence of increasing concentrations of UA derivatives was determined ( Figure 2) . The normalized residual activity values were reported in graphic versus inhibition concentrations and fitted by Equation 1.
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From that, it was found that 3, 5, and 7 were the most potent compounds (Figure 2) , with IC 50 values minor to 10 lM (Table 2) ; which allowed us to classify these compounds as hits, meanwhile compound 2 IC 50 was around 20 lM. The remaining compounds exhibited IC 50 values higher than 100 lM (graphics not shown). So, these values are similar to that described for UA (IC 50 5 3.08 lM) (Ramírez-Espinosa et al., 2011; Zhang et al., 2006) . All of these results correlate with the complete PTP-1B inhibition of the most active compounds with their corresponding low IC 50 values, and also explain in part, the reason why the remaining compounds did not show important inhibition values over PTP-1B. Also, in a previous work with oleanolic acid derivatives, we described that is necessary the presence of the carboxylic acid and/or its corresponding reduction product carbinol derivative (H-bond donor) in C-28 to maintain the inhibitory activity (Ramírez-Espinosa et al., 2014) . Thus, the fact that introducing a methyl ester in C-28 in UA to obtain compound 6, led to a weaker inhibition of enzymatic activity in current investigation.
Finally, for a better understanding of the type of enzymatic inhibition, an additional reversibility tests were performed. For that, the most active derivatives were incubated with an aliquot of PTP-1B during one hour. It is known that UA inhibits in a complete reversible manner (Ramírez-Espinosa et al., 2011) . From the data in Figure 3 , we argued that all compounds tested were PTP-1B reversible inhibitors, because the enzyme recovered its complete in vitro activity after compounds were eliminated, showing a similar performance as that reported for the parent compound UA (Ramírez-Espinosa et al., 2011) .
The potential of some triterpenic acids as promising PTP-1B inhibitors has been reported; however, these showed two main disadvantages: (1) they are not selective on this target, since these compounds inhibit other phosphatases, sharing 50-80% of homology with PTP-1B in their catalytic site, which represents a great challenge for to develop selective compounds;
(2) they have not the same potency/activity as the parent compound UA, which also has more selectivity to PTP-1B over other phosphatases (Zhang et al., 2006) . Owing to this, some UA derivatives have been developed in order to achieve better compounds. In our case, we found that three of the seven synthesized compounds showed important activity over PTP-1B with low IC 50 values; also, the inhibition caused by these derivatives was reversible. This is important since the irreversible inhibition of PTP-1B may cause overstimulation of insulin receptor, which finally can lead the desensitization of the receptor and/or side effects such as a drastic hypoglycemic effect.
To date, only one of the UA derivatives with significant antidiabetic effect has been reported, named UA0713, mediating PTP-1B inhibition (Zhang et al., 2006) . However, this compound was not a selective enzymatic inhibitor, because it displayed similar IC 50 values among PTP-1B and other phosphatases.
| Molecular docking with PTP-1B
In order to gain insight into the putative binding mode of compounds shows that AutoDock successfully predicted the binding mode of Table 3 . As it can be seen, compounds 3 and 5 showed the better D8G and Ki's calculated, which clearly correlates with its binding location that is the catalytic site. Moreover, both 3 and 5 were two of the three most in vitro active compounds of the entire series. Therefore, there exist an important correlation between docking prediction interactions with in vitro inhibitory activity on PTP-1B. In this context, the remaining compounds interacted with the extended B-binding site, and their D8G and Ki's calculated were less than the most active compounds 3 and 5, subsequently, the in vitro inhibitory activity shown by 1, 2, 4, and 6 were weaker or inactive. With exception of compound 7 that showed 
| In vivo antidiabetic effect
Based on the PTP-1B IC 50 values and inhibitory pattern, compounds 2 and 7 were selected to be evaluated through acute evaluation, on experimental noninsulin diabetic mice model (Figure 9 ). Compound 7 was selected because of its potent IC 50 value and its pattern as a nearly complete PTP-1B inhibitor, whilst derivative 2 was tested since its PTP-1B inhibition was moderated, in order to prove the potential correlation between in vitro and in vivo experiments.
The acute administration of 50 mg/kg of 7 showed a significant decrease in the variation of glycaemia (p < .05) from the first hour, and this effect was sustained until the end of the assay (7 h). This hypoglycemic effect over 70% was similar to the control drug glibenclamide, and better than the parent compound UA. Meanwhile, compound 2 did not show a significant effect within the three first hours of the acute assay; however, an important hypoglycemic effect was determined after fifth hour and until the end of the experiment, achieving a hypoglycemic effect value around 55%.
From these results, we conclude that derivative 7 presents a better in vivo acute hypoglycemic effect in comparison with 2. This observation can be explained by two points: (1) the derivative 7 IC 50 value was lower than 2, which means a better potency and inhibition of PTP-1B by compound 7, and therefore better sensibility to insulin action in the corresponding treated animals; and (2) it is proposed that 2 could be a prodrug, that is why we mentioned that the delayed effect (i.e., after 3 h of administration an effect was observed) could be due if 2 acts as a prodrug, this because after metabolism it could be transformed into UA, and then UA exerts its antidiabetic action; however, we have not explored that possibility yet. A similar approach has been reported with a different compound by Boutselis, Yu, Zhang, and Borch (2007) . It is important to show that both compounds had better pattern that the parent compound UA, and this poor hypoglycemic effect over this NIDDM model could be due to poor gut absorption.
| CON CL U S I ON
We prepared seven ursolic acid semisynthetic derivatives. Six compounds were prepared by microwave-assisted synthesis method, which allowed to improve reaction times although yields were variable. Compounds 3, 5, and 7 showed significant inhibitory activity on PTP-1B enzyme in a reversible manner. The most active compound was 7
showing important in vitro and in vivo effects. Furthermore, acetyl and crotonyl esters were the most active derivatives through in vitro 
